Sorry, you need to enable JavaScript to visit this website.

Use of Peptamen® Formula resulted in a decrease of $17,615 in total cost of care per patient in feeding intolerant patients who received home enteral nutrition.

Peptamen® formulas from Nestlé Health Science

In a retrospective study of 60 pediatric and adult patients in a post-acute care setting diagnosed with illnesses such as malignancy, hepato-biliary/pancreatic disorders and other GI conditions, use of Peptamen® formulas was associated with a 50.1% reduction in enteral feeding intolerance and a 45.5% decrease in cost of care.

When patients across multiple diagnoses received Peptamen® formulas, healthcare resource utilization improved at all time points up to 8 weeks as compared to the 4 weeks prior.

50.1% reduction inenteral feeding intolerance
45.5% decrease incost of care
Abstract Study Summary

The Use of Peptide-Based Diet in Enteral Nutrition Therapy: A Retrospective Cost Analysis

Osman Mohamed Elfadil, MBBS, Ankitaben Patel, MBBS, Raj N. Shah, MBBS, Ryan T. Hurt, MD, PhD, Manpreet S. Mundi, MD
Journal of Parenteral and Enteral Nutrition 2023;47(S2):S18.

Background

Home enteral nutrition (HEN) is often used to provide long-term nutrition therapy. Enteral feeding intolerance (EFI) is prevalent in HEN patients and often requires transition to a peptide-based tube feeding formula (PBF).

Objective

Determine the economic impact of using specialized formulas for the treatment of EFI in the HEN population.

Methods

This was a retrospective analysis of the Mayo Clinic Rochester HEN population data, evaluating the cost of transitioning to a 100% whey PBF during therapy from October 2018 through August 2020, with evaluation of demographic data, enteral nutrition (EN) regimen and cost of care being captured through October of 2020 or termination of EN.

Cost of care was categorized as follows:

  • Emergency Department visits-ED
  • Inpatient care-IP
  • Outpatient care-OP
  • Total cost of care-TC

Results

60patients included
Mean age53.5 ± 20.7years
55%female
Disease Process:
Malignancy
 

43.3%

Hepato-biliary/Pancreatic
 

15.0%

Mucosal Disease
 

10.0%

Non-Malignant Mechanical Obstruction
 

8.4%

Bariatric Surgery
 

8.4%

Gastrointestinal Dysmotility
 

6.6%

Neurodegenerative/Developmental Delay
 

6.6%

Functional Disorder
 

1.7%

  • Indication for EN included dysphagia/odynophagia, malnutrition, nausea and vomiting, fistula or bowel perforation, inadequate oral intake or obstruction/stricture.
EN Complications before and after PBF
Complications (%)
70% 60% 50% 40% 30% 20% 10% 0%

53.3%

 

48.3%

 

20.0%

 

28.3%

 

43.3%

 

↓ 50.1%21.6%

 

3.3%

 

10.0%

 
Overall
Tube-Related
EFI
Metabolic
 Pre-Transition %
 Post-Transition %
Pre-transition prevalence of EFI was43.3%
Post-transition prevalence of EFI was21.6%
Average cost of total care per patient on PBD
US Dollars
$50K $40K $30K $20K $10K $0

$38,744

 

$33,944

 

↓ 45.5%$21,129

 
Last 4 weeks prior to PBD
First 4 weeks of PBD
Second 4 weeks of PBD
 
Cost of Care Per Patient (Week - 4 to Week 8)
Cost of Care Per Patient (Week -4 to Week 8). Line graph of weekly cost of care per patient in US dollars, from week -4 before to week 8 after transition to a peptide-based diet, shown for Emergency Department Visits (ED), In Patient (IP), Out Patient (OP), and Total Cost of Care (TC).

ED = Emergency Department Visits IP = In Patient OP = Out Patient TC = Total Cost of Care

 
Conclusion

Use of 100% whey PBF improves EFI and results in a reduction in overall and itemized total cost of care.

USE UNDER MEDICAL SUPERVISION